- Home
- PHAR vs REAL Comparison
PHAR vs REAL Comparison
Compare PHAR & REAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- REAL
- Stock Information
- Founded
- PHAR 1988
- REAL 2011
- Country
- PHAR Netherlands
- REAL United States
- Employees
- PHAR N/A
- REAL N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- REAL Other Specialty Stores
- Sector
- PHAR Health Care
- REAL Consumer Discretionary
- Exchange
- PHAR Nasdaq
- REAL Nasdaq
- Market Cap
- PHAR 718.1M
- REAL 641.9M
- IPO Year
- PHAR N/A
- REAL 2019
- Fundamental
- Price
- PHAR $11.24
- REAL $5.34
- Analyst Decision
- PHAR Strong Buy
- REAL Buy
- Analyst Count
- PHAR 3
- REAL 5
- Target Price
- PHAR $30.00
- REAL $8.40
- AVG Volume (30 Days)
- PHAR 3.1K
- REAL 4.5M
- Earning Date
- PHAR 05-08-2025
- REAL 05-08-2025
- Dividend Yield
- PHAR N/A
- REAL N/A
- EPS Growth
- PHAR N/A
- REAL N/A
- EPS
- PHAR N/A
- REAL N/A
- Revenue
- PHAR $320,708,000.00
- REAL $616,717,000.00
- Revenue This Year
- PHAR $13.31
- REAL $11.45
- Revenue Next Year
- PHAR $7.68
- REAL $10.09
- P/E Ratio
- PHAR N/A
- REAL N/A
- Revenue Growth
- PHAR 24.13
- REAL 11.89
- 52 Week Low
- PHAR $6.65
- REAL $2.24
- 52 Week High
- PHAR $11.07
- REAL $11.38
- Technical
- Relative Strength Index (RSI)
- PHAR 69.87
- REAL 46.32
- Support Level
- PHAR $10.02
- REAL $4.98
- Resistance Level
- PHAR $10.89
- REAL $5.82
- Average True Range (ATR)
- PHAR 0.23
- REAL 0.33
- MACD
- PHAR 0.11
- REAL -0.00
- Stochastic Oscillator
- PHAR 100.00
- REAL 38.38
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.